Supporting a growing network of advocates fighting for HIV prevention and global health equity
Global and national policymakers, funders and partners, and researchers use various strategies to guide decisions on policy, funding and program choices. Civil society often has uneven and incomplete access to this information and are therefore less able to engage and advocate for inclusive and people-centered research, programs, products, and policies for HIV prevention that are based on evidence.
Together with our partners, AVAC supports and fortifies a robust network of bold and informed advocates and coalitions to advance inclusive, effective, people-centered policies and programs and we do this by:
podcast
In the days ahead under a new US Presidential Administration, advocacy for choice, freedom, science, and rights will require intentional strategies to protect hard fought gains in HIV treatment and prevention. And there will be major implications for the global AIDS response.
infographic
Oral PrEP initiations in Uganda were among the highest in the region, with sizable increases each quarter, until the enactment of the Anti-Homosexuality Act (AHA) in March 2023. Since then, the number of new PrEP initiations plummeted, and have since struggled to sustain rates seen in 2023. Public policies clearly matter.
podcast
Our debut episode of the Advocacy Chronicles features Yvette Raphael, the Executive Director of Advocacy for Prevention of HIV and AIDS (APHA) in South Africa, and a leader in the development of The Choice Manifesto.
Oral PrEP initiations in Uganda were among the highest in the region, with sizable increases each quarter, until the enactment of the Anti-Homosexuality Act (AHA) in March 2023. Since then, the number of new PrEP initiations plummeted, and have since struggled to sustain rates seen in 2023. Public policies clearly matter.
Fostering a network of deeply-informed, skilled and confident advocates to strengthen and expand advocacy for HIV prevention locally, regionally and globally.
Using training and mentorship from AVAC Fellow Alumni and other seasoned advocates to prepare the next generation of HIV prevention advocates.
Using data for smarter advocacy and high-impact campaigns.
We are in a period of profound uncertainty, remarkable progress and tremendous concern—for the state of the world, for the state of global health and HIV, and for the specific work that AVAC and our partners do. We’ve seen incredible advances in biomedical prevention in 2024 with the introduction of the dapivirine vaginal ring (DVR) and injectable cabotegravir (CAB) for PrEP and the spectacular clinical trial results of injectable lenacapavir—the combination of which could transform lives if rolled out with speed, scale and equity.